GlassScriptPhysician profile
Shaza Daoud
NPI 1063615375
$4,699.00
in general payments reported to CMS, 2019-2025
25 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $184 · 2021: $281 · 2022: $770 · 2023: $875 · 2024: $868 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,826 · Education: $59.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,825.89 |
| Education | $59.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.05 | 2019-2025 | Botox, Skyrizi |
| Allergan, INC. | $496.43 | 2019-2022 | |
| Amgen INC. | $494.24 | 2019-2025 | Otezla, Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $322.36 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $311.19 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $253.59 | 2019-2025 | Nemluvio |
| Pfizer INC. | $225.96 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.49 | 2023-2024 | Spevigo, Cyltezo |
| Epi Health, LLC | $172.99 | 2022 | |
| Genzyme Corporation | $146.21 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $128.84 | 2020-2025 | Jublia, Arazlo, Duobrii |
| Sun Pharmaceutical Industries INC. | $114.94 | 2021-2025 | |
| Incyte Corporation | $107.77 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $107.26 | 2022-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $100.09 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $91.00 | 2019 | |
| Ucb, INC. | $83.13 | 2021-2024 | Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $45.19 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $43.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.55 | 2021-2024 | |
| Verrica Pharmaceuticals INC. | $38.80 | 2023-2024 | Ycanth |
| Leo Pharma INC. | $29.24 | 2025 | Anzupgo |
| Organon LLC | $20.55 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $19.90 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $14.11 | 2025 | Hemangeol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaza Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.